Xalud Therapeutics

Xalud Therapeutics, Inc.Founded in 2009 and headquartered in New York, US, Xalud Therapeutics specializes in gene therapy for chronic inflammatory diseases.Xalud Therapeutics specializes in a non-viral plasmid DNA (pDNA)-delivered gene therapy platform, primarily focusing on treating chronic inflammatory conditions through the modulation of the immune system. Their flagship product, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10v), which functions as a potent anti-inflammatory cytokine targeting the root causes of inflammation. This innovative approach aims to restore homeostasis in the immune system, addressing various chronic inflammatory diseases, particularly in musculoskeletal and neurodegenerative indications. Xalud's technology is developed for a wide array of patients suffering from conditions such as osteoarthritis, multiple sclerosis, and neuropathic pain, expanding its potential client base significantly.Xalud Therapeutics operates through a business model focused on clinical trials and the development of gene therapies, predominantly generating revenue through partnerships and collaborations with research institutions and pharmaceutical companies. The company engages in B2B transactions, working closely with healthcare providers and clinical research organizations to facilitate the distribution and administration of its gene therapy products. The primary revenue stream derives from successful clinical trial completions and subsequent product approvals, leading to potential licensing agreements and collaborations that enhance market access.In May 2021, Xalud Therapeutics, Inc. The company plans to launch new products targeting chronic inflammatory conditions, while also aiming for geographical expansion into more major markets beyond the US as its research advances.

1. Series C

   May 18, 2021

   Amount

   $18M

   Investors

   Locked